ImmunoGen Reaffirms FY23 Sales Guidance, Excluding Elahere Sales, Between $45M-$50M
Portfolio Pulse from Benzinga Newsdesk
ImmunoGen has reaffirmed its FY23 sales guidance, excluding Elahere sales, to be between $45M-$50M.
November 02, 2023 | 10:33 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ImmunoGen's reaffirmation of its FY23 sales guidance, excluding Elahere sales, may instill confidence in investors, potentially leading to a positive impact on its stock price.
Reaffirming sales guidance is generally seen as a positive sign by investors as it indicates that the company is confident in its ability to meet its financial targets. This could lead to increased investor confidence in ImmunoGen, potentially leading to an increase in its stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100